Tevogen Bio establishes Philadelphia R&D Center to expedite product development in oncology, neurology and virology

New research & development center is located in Philadelphia’s Wanamaker Office Building

Warren-based Tevogen Bio on Tuesday said it opened a new Research & Development Center in Philadelphia’s historic Wanamaker Building to further expand the company’s R&D capability, allowing expansion of its precision T-cell product pipeline.

The company’s next-generation precision T-cell technology platform holds promise to deliver lifesaving innovations for viral infections, cancers and neurological conditions for which there is a high unmet need.

About Tevogen’s next-generation precision T-cell platform

Tevogen is investigating its technology’s potential to overcome the primary barriers to the broad application of personalized T-cell therapies: potency, purity, production-at-scale and patient-pairing, without the limitations of current approaches. Tevogen’s goal is to open the vast and unprecedented potential of developing personalized immunotherapies for large patient populations impacted by common cancers and viral infections.

The company’s lead product, TVGN-489, is currently in clinical trial for high-risk COVID-19 patients at Jefferson University Hospitals in Philadelphia. TVGN-489 is a highly purified, genetically unmodified, off-the-shelf, allogeneic SARS-CoV-2-specific cytotoxic CD8+ T lymphocyte product designed to detect targets spread across the entire viral genome.

The center will serve as the central location for the company’s product development initiatives and will house Tevogen’s global R&D leadership team.

The Wanamaker location accompanies Tevogen’s recently announced CIC Philadelphia facilities, which will provide the company with comprehensive research and product development capability. The highly equipped CIC laboratories will serve as a location for Tevogen’s ongoing preclinical research and will house its scientific and investigative teams.

“The addition of the Tevogen’s R&D Center, along with our CIC research facilities, will provide the company with comprehensive research and product development capability as we continue to explore the great potential of our precision T-cell technology,” Tevogen Chairman and CEO Dr. Ryan Saadi stated. “Our patients and investors both demand differentiated products, meaningful inventions and unrestricted access. We cannot spend billions and take decades to bring products of marginal values to the market. I am confident that Tevogen is going to disrupt the mold; in less than two years we have grown from a concept to a fully operational biotech powerhouse.”